NEW YORK (GenomeWeb News) – Caliper Life Sciences said today that based on a preliminary financial review it expects total revenues of $37.6 million for the fourth quarter of 2009, exceeding the company's revenue guidance of $33 to $35 million for the quarter.
The increased revenue figure was a result of stronger-than-anticipated revenues from its IVIS and LabChip products, as well as the benefit of licensing revenues from its recently announced microfluidic licensing deal with Becton Dickinson, which occurred one quarter earlier than anticipated.
Caliper's expected Q4 revenues would also be a 2.5 percent increase over the $36.7 million it reported in the fourth quarter of 2009.
The Hopkinton, Mass.-based firm also said that it expected full-year revenues of $119.6 million in 2009, down 11 percent from the $134.1 million in revenues it reported for 2008.
Caliper said it expects to report cash, cash equivalents, and marketable securities of approximately $38 million and outstanding short-term borrowings of approximately $15 million as of December 31, 2009. In addition, the company said that it expects to report positive operating cash flows on a full-year basis for 2009, one year ahead of previous guidance.